Molecular profiling of dilated cardiomyopathy that progresses to heart failure

JCI Insight

Volumn 1, Issue 6, 2016, Pages

  Burke, Michael A ^a,b   Chang, Stephen ^b   Wakimoto, Hiroko ^b   Gorham, Joshua M ^b   Conner, David A ^b   Christodoulou, Danos C ^b   Parfenov, Michael G ^b   DePalma, Steve R ^b   Eminaga, Seda ^b   Konno, Tetsuo ^b   Seidman, Jonathan G ^b   Seidman, Christine E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84994266918     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.86898     Document Type: Article

References (54)

1. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013; 10(9):531-547.
2. Gorski PA, Ceholski DK, Hajjar RJ. Altered myocardial calcium cycling and energetics in heart failure-a rational approach for disease treatment. Cell Metab. 2015; 21(2):183-194.
3. Schmitt JP, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003; 299(5611):1410-1413.
4. Truszkowska GT, et al. A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations. BMC Med Genet. 2015; 16:21.
5. Fish M, et al. Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. Sci Rep. 2016; 6:22235.
6. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999; 281(7):650-655.
7. Thaman R, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart. 2005; 91(7):920-925.
8. Harris KM, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006; 114(3):216-225.
9. Geisterfer-Lowrance AA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science. 1996; 272(5262):731-734.
10. Christodoulou DC, et al. 5'RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. J Clin Invest. 2014; 124(3):1364-1370.
11. Cucoranu I, et al. NAD(P)H oxidase 4 mediates transforming growth factor-β1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005; 97(9):900-907.
12. Kim W, et al. RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation. Proc Natl Acad Sci U S A. 2014; 111(46):16389-16394.
13. Raaz U, et al. Transcription factor Runx2 promotes aortic fibrosis and stiffness in type 2 diabetes mellitus. Circ Res. 2015; 117(6):513-524.
14. Mullen AC, et al. Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell. 2011; 147(3):565-576.
15. Braitsch CM, Kanisicak O, van Berlo JH, Molkentin JD, Yutzey KE. Differential expression of embryonic epicardial progenitor markers and localization of cardiac fibrosis in adult ischemic injury and hypertensive heart disease. J Mol Cell Cardiol. 2013; 65:108-119.
16. Sazonova O, et al. Characterization of TCF21 downstream target regions identifies a transcriptional network linking multiple independent coronary artery disease loci. PLoS Genet. 2015; 11(5):e1005202.
17. Ponticos M, Harvey C, Ikeda T, Abraham D, Bou-Gharios G. JunB mediates enhancer/promoter activity of COL1A2 following TGF-β induction. Nucleic Acids Res. 2009; 37(16):5378-5389.
18. Perry MC, et al. ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction. Mol Cell Biol. 2014; 34(23):4232-4243.
19. Faherty N, et al. TGFβ and CCN2/CTGF mediate actin related gene expression by differential E2F1/CREB activation. BMC Genomics. 2013; 14:525.
20. Zhang Y, et al. E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr-1/SHP/EID1 network. Hepatology. 2014; 60(3):919-930.
21. Brooks AC, DeMartino AM, Brainard RE, Brittian KR, Bhatnagar A, Jones SP. Induction of activating transcription factor 3 limits survival following infarct-induced heart failure in mice. Am J Physiol Heart Circ Physiol. 2015; 309(8):H1326-H1335.
22. Koren L, et al. ATF3-dependent cross-talk between cardiomyocytes and macrophages promotes cardiac maladaptive remodel ing. Int J Cardiol. 2015; 198:232-240.
23. Liu Y, et al. Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells. Proc Natl Acad Sci U S A. 2007; 104(10):3859-3864.
24. Singh R, et al. Tbx20 interacts with smads to confine tbx2 expression to the atrioventricular canal. Circ Res. 2009; 105(5):442-452.
25. Dawson K, Aflaki M, Nattel S. Role of the Wnt-Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential. J Physiol. 2013; 591(6):1409-1432.
26. Lee KY, et al. Tbx15 controls skeletal muscle fibre-type determination and muscle metabolism. Nat Commun. 2015; 6:8054.
27. Teekakirikul P, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest. 2010; 120(10):3520-3529.
28. Chen W, Zhang X, Birsoy K, Roeder RG. A muscle-specific knockout implicates nuclear receptor coactivator MED1 in the regulation of glucose and energy metabolism. Proc Natl Acad Sci U S A. 2010; 107(22):10196-10201.
29. Yaxing Z, Xiao-Jing Z, Hongliang L. Targeting interferon regulatory factor for cardiometabolic diseases: opportunities and challenges [published online ahead of print August 4, 2015]. Curr Drug Targets. PMID: 26240052.
30. Mann DL, Topkara VK, Evans S, Barger PM. Innate immunity in the adult mammalian heart: for whom the cell tolls. Trans Am Clin Climatol Assoc. 2010; 121:34-50.
31. Okamoto H, Imanaka-Yoshida K. Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc Ther. 2012; 30(4):e198-209.
32. Frantz S, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999; 104(3):271-280.
33. Schilling J, Lai L, Sambandam N, Dey CE, Leone TC, Kelly DP. Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor γ coactivator-1 signaling. Circ Heart Fail. 2011; 4(4):474-482.
34. Dvorak HF. Tumors: wounds that do not heal-redux. Cancer Immunol Res. 2015; 3(1):1-11.
35. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol. 2013; 10(1):15-26.
36. Akhmetshina A, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 2012; 3:735.
37. Chopra S, Kumar N, Rangarajan A, Kondaiah P. Context dependent non canonical WNT signaling mediates activation of fibroblasts by transforming growth factor-β. Exp Cell Res. 2015; 334(2):246-259.
38. Min KW, et al. NAG-1/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway. Oncogene. 2016; 35(3):377-388.
39. Arany Z, et al. Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005; 1(4):259-271.
40. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1α. Proc Natl Acad Sci U S A. 2006; 103(26):10086-10091.
41. Puente BN, et al. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response. Cell. 2014; 157(3):565-579.
42. Carley AN, Taglieri DM, Bi J, Solaro RJ, Lewandowski ED. Metabolic efficiency promotes protection from pressure overload in hearts expressing slow skeletal troponin I. Circ Heart Fail. 2015; 8(1):119-127.
43. Wang ZV, et al. Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway. Cell. 2014; 156(6):1179-1192.
44. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-1033.
45. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000; 106(7):847-856.
46. Russell LK, et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator-1α promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004; 94(4):525-533.
47. Djouadi F, et al. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor α- deficient mice. J Clin Invest. 1998; 102(6):1083-1091.
48. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-α-null hearts can be rescued by increasing glucose transport and utilization. Circulation. 2005; 112(15):2339-46.
49. Smeets PJ, et al. Cardiac hypertrophy is enhanced in PPARα-/- mice in response to chronic pressure overload. Cardiovasc Res. 2008; 78(1):79-89.
50. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007; 115(4):518-533.
51. Villena JA, Kralli A. ERRα: a metabolic function for the oldest orphan. Trends Endocrinol Metab. 2008; 19(8):269-276.
52. Fatkin D, et al. An abnormal Ca2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest. 2000; 106(11):1351-1359.
53. Liao R, Jain M. Isolation, culture, and functional analysis of adult mouse cardiomyocytes. Methods Mol Med. 2007; 139:251-262.
54. Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 2010; 11(2):R14.